Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
zDnrq6KHVtF0ZbLy
